PAVmed Launches Veris Cancer Care Platform in Partnership with Ohio State University for Enhanced Treatment

PAVmed's Innovative Partnership Enhances Cancer Care Through Technology

PAVmed Inc., a prominent player in the medical technology sector, marks a significant advancement in cancer treatment with the commercial launch of its Veris Cancer Care Platform. This initiative is in collaboration with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a premier National Cancer Institute-designated center. The partnership aims to revolutionize personalized cancer care for patients undergoing systemic therapy, leveraging technology to improve outcomes and enhance patient experiences. Brian deGuzman, M.D., COO of Veris Health, describes this launch as a crucial milestone, setting the stage for the platform’s expansive commercial potential in the realm of oncology.

The Veris Cancer Care Platform is a multifaceted digital solution designed to facilitate remote physiological data collection, symptom reporting, and telehealth services, all seamlessly integrated with electronic health records. This innovative approach not only empowers healthcare providers to detect complications early but also aims to minimize unplanned hospitalizations, a common challenge in cancer treatment. By employing longitudinal data trends and risk management tools, the platform enhances the ability of clinicians to make informed decisions regarding patient care, which is critical in a field where timely interventions can significantly impact treatment efficacy and patient quality of life.

Patients who enroll in the Veris program receive a VerisBox™, which contains a suite of connected health devices that continuously transmit health data to a cloud-based clinician portal. Additionally, a smartphone application provides patients with a dedicated portal to report symptoms and monitor health parameters. This technology fosters communication among patients, their families, and healthcare providers, ensuring that all stakeholders are informed and engaged throughout the treatment journey. As Dr. David Cohn, COO and CMO at The James Cancer Hospital, states, this collaboration represents a pivotal step in their mission to provide innovative and personalized cancer care, further enhancing the connection with patients beyond traditional hospital settings.

In conjunction with the platform launch, PAVmed and OSUCCC – James are establishing a clinical registry for patients utilizing the Veris Cancer Care Platform. This registry is expected to enhance the research capabilities of OSUCCC – James, allowing for deeper insights into patient experiences and treatment outcomes. The data collected will not only support individualized patient care but also contribute to broader cancer research efforts.

Overall, this partnership signifies PAVmed's commitment to advancing cancer care through cutting-edge technology while addressing the complexities of treatment management. The Veris Cancer Care Platform is poised to redefine patient engagement and support systems in oncology, reflecting a growing trend towards personalized, data-driven healthcare solutions.